N4-(3-Bromophenyl)-7-(substituted benzyl) pyrrolo[ 2,3-d]pyrimidines as potent multiple receptor tyrosine kinase inhibitors: Design, synthesis, and in vivo evaluation

被引:16
作者
Gangjee, Aleem [1 ]
Zaware, Nilesh [1 ]
Raghavan, Sudhir [1 ]
Yang, Jie [1 ]
Thorpe, Jessica E. [2 ]
Ihnat, Michael A. [2 ]
机构
[1] Duquesne Univ, Div Med Chem, Grad Sch Pharmaceut Sci, Pittsburgh, PA 15282 USA
[2] Univ Oklahoma, Dept Cell Biol, Hlth Sci Ctr, Sch Med, Oklahoma City, OK 73104 USA
基金
美国国家卫生研究院;
关键词
Multiple receptor; Tyrosine kinase inhibitors; Antiangiogenic agents; ENDOTHELIAL GROWTH-FACTOR; CELL LUNG-CANCER; THYMIDYLATE SYNTHASE; ANTITUMOR AGENTS; ANGIOGENESIS; THERAPY; TUMOR; PROLIFERATION; COMBINATION; RESISTANCE;
D O I
10.1016/j.bmc.2012.01.029
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
With the goal of developing multitargeted receptor tyrosine kinase inhibitors that display potent inhibition against PDGFR beta and VEGFR-2 we designed and synthesized eleven N-4-(3-bromophenyl)-7-(substitutedbenzyl) pyrrolo[2,3-d]pyrimidines 9a-19a. These compounds were obtained from the key intermediate N4-(3-bromophenyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine 29. Various arylmethyl groups were regiospecifically attached at the N7 of 29 via sodium hydride induced alkylation with substituted arylmethyl halides. Compounds 11a and 19a were potent dual inhibitors of PDGFRb and VEGFR-2. In a COLO-205, in vivo tumor mouse model 11a demonstrated inhibition of tumor growth, metastasis, and tumor angiogenesis that was better than or comparable to the standard compound TSU-68 (SU6668, 8). (C) 2012 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2444 / 2454
页数:11
相关论文
共 45 条
[1]  
[Anonymous], MOL OP ENV MOE 2008
[2]  
[Anonymous], FLEXX 3 1 2
[3]   Oncogenic kinase signalling [J].
Blume-Jensen, P ;
Hunter, T .
NATURE, 2001, 411 (6835) :355-365
[4]   Platelet-derived growth factor receptor (PDGFR): A target for anticancer therapeutics [J].
Board, R ;
Jayson, GC .
DRUG RESISTANCE UPDATES, 2005, 8 (1-2) :75-83
[5]   Angiogenesis in health and disease [J].
Carmeliet, P .
NATURE MEDICINE, 2003, 9 (06) :653-660
[6]   Receptor-Based Virtual Screening of EGFR Kinase Inhibitors from the NCI Diversity Database [J].
Choowongkomon, Kiattawee ;
Sawatdichaikul, Orathai ;
Songtawee, Napat ;
Limtrakul, Jumras .
MOLECULES, 2010, 15 (06) :4041-4054
[7]   Sunitinib: From rational design to clinical efficacy [J].
Chow, Laura Q. M. ;
Eckhardt, S. Gail .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (07) :884-896
[8]   The current situation:: Erlotinib (Tarceva®) and gefitinib (Iressa®) in non-small cell lung cancer [J].
Comis, RL .
ONCOLOGIST, 2005, 10 (07) :467-470
[9]   Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy [J].
Dvorak, HF .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (21) :4368-4380
[10]   Combined inhibition of VEGF- and PDGF-signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms [J].
Erber, R ;
Thurnher, A ;
Katsen, AD ;
Groth, G ;
Kerger, H ;
Hammes, HP ;
Menger, MD ;
Ullrich, A ;
Vajkoczy, P .
FASEB JOURNAL, 2003, 17 (15) :338-340